These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26976811)

  • 1. Detrimental Effects of "Stretch" Goals in Specialty Substance Use Disorder Treatment Organizations.
    Lemoine GJ; Blum TC; Roman PM
    J Subst Abuse Treat; 2016 May; 64():13-23. PubMed ID: 26976811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.
    Abraham AJ; Knudsen HK; Rieckmann T; Roman PM
    J Stud Alcohol Drugs; 2013 Mar; 74(2):258-65. PubMed ID: 23384373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of Network for the Improvement of Addiction Treatment (NIATx) Processes in Substance Use Disorder Treatment Centers.
    Fields D; Knudsen HK; Roman PM
    J Behav Health Serv Res; 2016 Jul; 43(3):354-65. PubMed ID: 25934355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The United States' Federal Parity Act and treatment of substance use disorders: Administrators' familiarity and perceptions of impact.
    Edmond MB; Aletraris L; Roman PM; Fields DL; Bride BE
    Int J Drug Policy; 2016 Aug; 34():80-7. PubMed ID: 27450320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organizing Publicly Funded Substance Use Disorder Treatment in the United States: Moving Toward a Service System Approach.
    Padwa H; Urada D; Gauthier P; Rieckmann T; Hurley B; Crèvecouer-MacPhail D; Rawson RA
    J Subst Abuse Treat; 2016 Oct; 69():9-18. PubMed ID: 27568505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining trends in substance use disorder capacity and service delivery by Health Resources and Services Administration-funded health centers: A time series regression analysis.
    Pourat N; O'Masta B; Chen X; Lu C; Zhou W; Daniel M; Hoang H; Sripipatana A
    PLoS One; 2020; 15(11):e0242407. PubMed ID: 33253263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring Diversification as A Management Strategy in Substance Use Disorder Treatment Organizations.
    Fields D; Riesenmy K; Roman PM
    J Subst Abuse Treat; 2015 Oct; 57():63-9. PubMed ID: 26021404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Improvements in Measured Performance Driven by Better Treatment or "Denominator Management"?
    Harris AH; Chen C; Rubinsky AD; Hoggatt KJ; Neuman M; Vanneman ME
    J Gen Intern Med; 2016 Apr; 31 Suppl 1(Suppl 1):21-7. PubMed ID: 26951270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of organization and management in private and public substance abuse treatment programs.
    Roman PM; Ducharme LJ; Knudsen HK
    J Subst Abuse Treat; 2006 Oct; 31(3):235-43. PubMed ID: 16996386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management systems, patient quality improvement, resource availability, and substance abuse treatment quality.
    Fields D; Roman PM; Blum TC
    Health Serv Res; 2012 Jun; 47(3 Pt 1):1068-90. PubMed ID: 22098342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights from a national survey into why substance abuse treatment units add prevention and outreach services.
    Wells R; Lemak CH; D'Aunno TA
    Subst Abuse Treat Prev Policy; 2006 Aug; 1():21. PubMed ID: 16887037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Directed funding to address under-provision of treatment for substance use disorders: a quantitative study.
    Frakt AB; Trafton J; Wallace A; Neuman M; Pizer S
    Implement Sci; 2013 Jul; 8():79. PubMed ID: 23866119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of off-label medications in substance abuse treatment programs.
    Paino M; Aletraris L; Roman PM
    Subst Abus; 2020; 41(3):340-346. PubMed ID: 31361567
    [No Abstract]   [Full Text] [Related]  

  • 15. Science-based and practice-based innovativeness and performance of substance abuse treatment facilities.
    Nayar P; Yu F; Apenteng B
    Health Care Manage Rev; 2014; 39(1):66-74. PubMed ID: 23358133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of Care in the Implementation of the Affordable Care Act: Changes in Treatment Services in a National Sample of Centers Treating Substance Use Disorders.
    Aletraris L; Roman PM; Pruett J
    J Psychoactive Drugs; 2017; 49(2):132-140. PubMed ID: 28350226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organizational factors associated with the use of contingency management in publicly funded substance abuse treatment centers.
    Bride BE; Abraham AJ; Roman PM
    J Subst Abuse Treat; 2011 Jan; 40(1):87-94. PubMed ID: 20850259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Examination of Medical Staff Utilization in Substance Use Disorder Treatment Organizations.
    Fields D; Roman P
    J Subst Abuse Treat; 2015 Dec; 59():94-8. PubMed ID: 26219681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of organization and management in substance abuse treatment: Review and roadmap.
    D'Aunno T
    J Subst Abuse Treat; 2006 Oct; 31(3):221-33. PubMed ID: 16996385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.
    Knudsen HK; Roman PM
    J Stud Alcohol Drugs; 2014 May; 75(3):476-85. PubMed ID: 24766760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.